Literature DB >> 25389307

Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.

Rosemary M McCloskey1, Richard H Liang1, Jeffrey B Joy1, Mel Krajden2, Julio S G Montaner3, P Richard Harrigan3, Art F Y Poon3.   

Abstract

Hepatitis C virus (HCV) has a naturally occurring polymorphism, Q80K, in the nonstructural protein 3 (NS3) gene encoding the viral protease, which has been associated with reduced susceptibility to the direct-acting antiviral inhibitor simeprevir. Q80K is observed predominantly in HCV genotype 1a and seldom in other HCV genotypes; moreover, it has a markedly high prevalence in the United States. Here, we reconstruct the evolutionary history of this polymorphism to investigate why it is so highly localized in prevalence and whether it is stably transmitted between hosts. We found that the majority (96%) of HCV infections carrying Q80K were descended from a single lineage in which a Q80K substitution occurred around the 1940s in the United States, which implies that this polymorphism is likely highly transmissible. Furthermore, we identified 2 other substitutions in NS3 that may interact with Q80K and contribute to its stability. Our results imply that the current distribution and prevalence of Q80K are unlikely to change significantly in the short term.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Q80K; ancestral reconstruction; hepatitis C virus; molecular phylogenetics; phylogeography; simeprevir; virus evolution

Mesh:

Substances:

Year:  2014        PMID: 25389307     DOI: 10.1093/infdis/jiu613

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

Review 1.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

2.  Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.

Authors:  Enass A Abdel-Hameed; Susan D Rouster; Xiang Zhang; Jing Chen; Mario Medvedovic; Zachary D Goodman; Kenneth E Sherman
Journal:  J Acquir Immune Defic Syndr       Date:  2017-03-01       Impact factor: 3.731

3.  Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.

Authors:  C K S Chui; W W Y Dong; J B Joy; A F Y Poon; W Y Dong; T Mo; C K Woods; C Beatty; H Hew; P R Harrigan; C J Brumme
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

4.  Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6.

Authors:  Juan Ángel Patiño-Galindo; Karina Salvatierra; Fernando González-Candelas; F Xavier López-Labrador
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 5.  Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.

Authors:  Miguel Jiménez-Pérez; Rocío González-Grande; Pilar España Contreras; Isabel Pinazo Martínez; Jesús de la Cruz Lombardo; Raúl Olmedo Martín
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

6.  Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.

Authors:  Preethi Krishnan; Rakesh Tripathi; Gretja Schnell; Thomas Reisch; Jill Beyer; Michelle Irvin; Wangang Xie; Lois Larsen; Daniel Cohen; Thomas Podsadecki; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 7.  Resistance to DAAs: When to Look and When It Matters.

Authors:  David L Wyles
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

8.  Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.

Authors:  Andrea De Luca; Simona Di Giambenedetto; Alessandra Lo Presti; Saleta Sierra; Mattia Prosperi; Eleonora Cella; Marta Giovanetti; Carlo Torti; Cinzia Caudai; Ilaria Vicenti; Francesco Saladini; Paolo Almi; Pierfrancesco Grima; Pierluigi Blanc; Massimiliano Fabbiani; Barbara Rossetti; Roberta Gagliardini; Rolf Kaiser; Massimo Ciccozzi; Maurizio Zazzi
Journal:  Open Forum Infect Dis       Date:  2015-03-31       Impact factor: 3.835

Review 9.  Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications.

Authors:  Celia Perales; Josep Quer; Josep Gregori; Juan Ignacio Esteban; Esteban Domingo
Journal:  Viruses       Date:  2015-11-06       Impact factor: 5.048

10.  Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.

Authors:  Preethi Krishnan; Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Xinyan Zhang; Carolyn Setze; Lino Rodrigues; Margaret Burroughs; Rebecca Redman; Kazuaki Chayama; Hiromitsu Kumada; Christine Collins; Tami Pilot-Matias
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.